ArticleScientific reports2026
Brain-derived microvesicles induce activation of aspirin-treated platelets via the PLC/PKC pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Aspirin (Asp) therapy reduces the risk of arterial thrombotic events. However, aspirin-related adverse effects, particularly cerebral hemorrhage with its high mortality and disability rates, remain a significant concern. Interestingly, long-term antiplatelet therapy does not appear to exacerbate bleeding severity in patients with hemorrhagic cerebrovascular disease, suggesting potential compensatory mechanisms inducing platelet activation post-hemorrhage. Brain-derived microvesicles (BDMVs) have been implicated in platelet activation, although the underlying molecular mechanisms are unclear. This study employed flow cytometry (FCM), ELISA, and hopping probe ion conductance microscopy (HPICM) to demonstrate that BDMVs significantly activate and induce morphological changes in aspirin-treated platelets. We discovered the presence of cyclooxygenase-1 (COX-1) on BDMVs. Then, the phosphorylated proteomics was used to analyze the effect of BDMVs on aspirin-treated platelet quantitatively and validate the involvement of several signaling molecules. Biological validation showed that BDMVs increased phospholipase C (PLC), protein kinase C (PKC) and Akt phosphorylation. We also used PLC inhibitor U73122 to treat BDMV-intervened platelet and found reduced phosphorylation of the downstream signaling molecule PKC. These findings suggest that COX-1 within BDMVs may partially counteract the inhibitory effect of aspirin on platelets. Furthermore, BDMVs, combined with arachidonic acid (AA), activate aspirin-treated platelets and suggest the involvement of the PLC/PKC pathway. This study provides a theoretical basis for the early treatment of patients with clinical aspirin-related cerebral hemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.